Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2109238 Target Snapshot

Neuronal acetylcholine receptor; alpha9/alpha10 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
246Compounds
75Assays
1Approved Drugs
151.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Neuronal acetylcholine receptor; alpha9/alpha10 shows late clinical disease relevance led by Tinnitus. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q9UGM1. Start with Tinnitus, then reuse UniProt Q9UGM1 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Tinnitus, then reuse UniProt Q9UGM1 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
Tinnitus

Neuronal acetylcholine receptor; alpha9/alpha10 shows late clinical disease relevance led by Tinnitus. 1 linked drug remains visible in the same block.

Start review with Tinnitus because it currently carries late clinical support. Linked drugs include NERAMEXANE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Protein anchor
Neuronal acetylcholine receptor subunit alpha-9

Neuronal acetylcholine receptor subunit alpha-9

Review this target as Neuronal acetylcholine receptor; alpha9/alpha10, mapped to UniProt Q9UGM1. ChEMBL maps the protein component as Neuronal acetylcholine receptor subunit alpha-9. Sequence length is 479 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9UGM1 Protein 479 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Neuronal acetylcholine receptor; alpha9/alpha10 as ChEMBL target CHEMBL2109238, mapped to UniProt Q9UGM1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Neuronal acetylcholine receptor; alpha9/alpha10
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2109238
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9UGM1
Neuronal acetylcholine receptor subunit alpha-9
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Neuronal acetylcholine receptor; alpha9/alpha10 is the right protein anchor across sources, using UniProt Q9UGM1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Tinnitus is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNeuronal acetylcholine receptor; alpha9/alpha10
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtQ9UGM1
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNeuronal acetylcholine receptor subunit alpha-9
UniProt AccessionQ9UGM1
Component TypeProtein
Sequence Length479 aa

Neuronal acetylcholine receptor subunit alpha-9

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Neuronal acetylcholine receptor; alpha9/alpha10, mapped to UniProt Q9UGM1. ChEMBL maps the protein component as Neuronal acetylcholine receptor subunit alpha-9. Sequence length is 479 aa.

Mapped IDQ9UGM1
Review nameNeuronal acetylcholine receptor; alpha9/alpha10
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Neuronal acetylcholine receptor; alpha9/alpha10 shows late clinical disease relevance led by Tinnitus.

Late clinical Phase III
Tinnitus
1 linked drug · 1 direct · 1 efficacy
Linked drugNERAMEXANE MESYLATE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Tinnitus because it currently carries late clinical support. Linked drugs include NERAMEXANE MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseTinnitus
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC50135.0
EC5016.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5219936 10.3 IC50 0.05 Preclinical
CHEMBL5219016 9.59 IC50 0.26 Preclinical
CHEMBL5220467 9.47 IC50 0.34 Preclinical
CHEMBL5219752 9.44 IC50 0.36 Preclinical
CHEMBL5220455 9.41 IC50 0.39 Preclinical
CHEMBL5220113 9.4 IC50 0.4 Preclinical
CHEMBL5086734 9.3 IC50 0.5 Preclinical
CHEMBL5219791 9.29 IC50 0.51 Preclinical
CHEMBL267841 9.25 IC50 0.56 Preclinical
CHEMBL5090753 9.05 IC50 0.9 Preclinical
Distribution

pChEMBL Value Distribution

8
5.0
7
5.5
22
6.0
7
6.5
10
7.0
13
7.5
19
8.0
13
8.5
8
9.0
1
9.5
pChEMBL
Assay Landscape

Assay Landscape

75
Total Assays
107
Tested Compounds
2
Assay Types
Binding — 73 assays, 107 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 57 92 7.1
assay format 12 11 6.0
protein complex format 4 4 6.4
Functional — 2 assays, 8 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 8 8.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine